Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235085 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
A Phase 3 study of Non-Proliferative Diabetic Retinopathy, sponsored by Ocular Therapeutix.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 930
- Enrollment target
- 1
- Study location
NCT07235085 is a Phase 3 study of Non-Proliferative Diabetic Retinopathy that is actively recruiting participants, run by Ocular Therapeutix. The registered enrollment target is 930 participants, above the 117-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (695% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07235085, a Phase 3 study of Non-Proliferative Diabetic Retinopathy, is actively recruiting participants, sponsored by Ocular Therapeutix.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 930 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into the vitreous cavity of the eye, the hydrogel begins to slowly break down, which allows the axitinib to be slowly released over time. This clinical trial is comparing OTX-TKI to a "sham" injection procedure. The sham injection is a mock injection procedure, but nothing will actually be inserted in the eye as there is no needle on the sham injector. Only one eye ("study eye") will be treated with study treatment.
Conditions Studied
Interventions
- DRUG Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
- DRUG Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
- OTHER Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
Study Locations (1)
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 930 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07235085
The ClinicalTrials.gov registry entry for NCT07235085 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 930 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 117-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (695% higher). The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 3 interventions - of which Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 is the first listed.
NCT07235085 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07235085 about?
NCT07235085 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy". The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into the vitreous cavity ...
What is the current status of trial NCT07235085?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 930 participants. The study started on 2025-11-17. Estimated completion is 2027-03.
What conditions does trial NCT07235085 study?
This clinical trial studies the following conditions: Non-Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT07235085?
The interventions under investigation include: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 (DRUG), Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 (DRUG), Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24 (OTHER).
Who is sponsoring clinical trial NCT07235085?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235085 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of Faricimab in Patients With NPDR
COMPLETED · Phase 2
-
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Diabetes Visual Function Supplement Study
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.